INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2011 in Chicago, Illinois. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The data presentation at ASCO 2011 will highlight the safety, tolerability and activity profile of SF1126 in patients with advanced solid tumors and B-cell malignancies.
